eMedicine Specialties > Urology > Infections and Related Inflammatory Conditions

Fournier Gangrene: Treatment

Author: Thomas Santora, MD, Professor and Vice-Chair for Clinical Affairs, Department of Surgery, Temple University Hospital and School of Medicine
Coauthor(s): Daniel B Rukstalis, MD, Director of Urological Services, Geisinger Medical Center, Geisinger Medical Group
Contributor Information and Disclosures

Updated: Mar 19, 2009

Treatment

Medical Therapy

Treatment of Fournier gangrene involves several modalities, including restoration of normal organ perfusion. In patients who present with systemic toxicity manifesting as hypoperfusion or organ failure, aggressive resuscitation to return normal organ perfusion and function must take precedence over diagnostic maneuvers, especially if these diagnostic studies could compromise the resuscitative interventions.

Treatment of Fournier gangrene also involves the institution of broad-spectrum antibiotic therapy. The antibiotic spectrum should cover staphylococci, streptococci, the Enterobacteriaceae family of organisms, and anaerobes. A reasonable empiric regimen might consist of ciprofloxacin and clindamycin. Clindamycin is particularly useful in the treatment of necrotizing soft-tissue infections because of its gram-positive and anaerobic spectrum of activity. In animal models of streptococcal infection, clindamycin has been shown to yield response rates superior to those of penicillin or erythromycin, even in the context of delayed treatment.31

If initial tissue stains (ie, KOH stain) show fungi, add an empiric antifungal agent such as amphotericin B or caspofungin. In cases associated with sepsis syndrome, therapy with intravenous immunoglobulin (IVIG), which is thought to neutralize superantigens such as the streptotoxins (A, B) believed to mitigate the exaggerated cytokine response, has been shown to be a good adjuvant to appropriate antibiotic coverage and complete surgical debridement.32

Hyperbaric oxygen, if available, has shown some promising results.33,34,35 This therapy needs to be balanced with the stability of the patient. Surgical debridement must not be delayed for consideration of hyperbaric oxygen.

In addition to the above treatment interventions used to address the infectious process, the underlying comorbid conditions that frequently coexist and that potentially predispose to Fournier gangrene must ultimately be addressed. For example, blood sugar needs to be controlled in patients with diabetes, and alcohol withdrawal needs to be addressed in patients with alcoholism. Failure to adequately manage the comorbid conditions may threaten the success of even the most appropriate interventions to resolve the infectious disease.

Surgical Therapy

  • Establishing the diagnosis
    • In the event of a presumptive diagnosis based on a clinical examination or diagnostic study, the definitive diagnosis of Fournier gangrene is established by examination with the patient under anesthesia followed by incision into the area of greatest clinical concern.
    • If frankly gangrenous tissue is found or purulence is drained (see Image 7), the diagnosis of Fournier gangrene is established.

      The same patient depicted in Image 6. The scrotum...

      The same patient depicted in Image 6. The scrotum has been opened along the median raphe, which liberated foul-smelling brown purulence and exposed necrotic tissue throughout the mid scrotum. The testicles were not involved. Courtesy of Thomas A. Santora, MD.

      The same patient depicted in Image 6. The scrotum...

      The same patient depicted in Image 6. The scrotum has been opened along the median raphe, which liberated foul-smelling brown purulence and exposed necrotic tissue throughout the mid scrotum. The testicles were not involved. Courtesy of Thomas A. Santora, MD.

    • Occasionally, early-stage Fournier disease manifests as severe cellulitis. If an incision is made, the fascia may appear edematous rather than the gray-black appearance of well-established Fournier gangrene. In this instance, obtain an incisional biopsy sample of the deep fascia for frozen-section evaluation to eliminate the potential for early necrotizing disease.
  • Excising necrotic tissue
    • Once a diagnosis of Fournier gangrene is established, all necrotic tissue must be excised. The skin should be opened widely to expose the full extent of the underlying fascial and subcutaneous tissue necrosis. All fascial planes that separate easily with blunt dissection should be considered involved and therefore excised. The dissection should be carried out to include bleeding tissues (ie, tissue that is well vascularized).
    • Send tissue for aerobic and anaerobic cultures and a histologic assessment.
    • Given the characteristic thrombosis of the nutrient vessels, the overlying skin has impaired blood supply and should be excised if significantly undermined. The authors strongly recommend radical excisional debridement (see Image 4) with electrocautery in order to reduce the considerable operative blood loss if the area of involvement is extensive.

      The same patient depicted in Image 3, following t...

      The same patient depicted in Image 3, following the first radical debridement procedure. A dorsal slit was made in the prepuce to expose the glans penis. Urethral catheterization was performed. Incision into the point of maximal tenderness on the right side of the perineum revealed gangrenous necrosis that involved the anterior and posterior aspects of the perineum, the entirety of the right hemiscrotum, and the posterior medial aspect of the right thigh. The skin and involved fascia were excised from these areas. Reconstruction of this defect was performed in a staged approach. A gracilis rotational muscle flap taken from the right thigh was used to fill the cavity in the posterior right perineum as the first step. The remainder of the defect was covered with split-thickness skin grafts. This patient made a full recovery.

      The same patient depicted in Image 3, following t...

      The same patient depicted in Image 3, following the first radical debridement procedure. A dorsal slit was made in the prepuce to expose the glans penis. Urethral catheterization was performed. Incision into the point of maximal tenderness on the right side of the perineum revealed gangrenous necrosis that involved the anterior and posterior aspects of the perineum, the entirety of the right hemiscrotum, and the posterior medial aspect of the right thigh. The skin and involved fascia were excised from these areas. Reconstruction of this defect was performed in a staged approach. A gracilis rotational muscle flap taken from the right thigh was used to fill the cavity in the posterior right perineum as the first step. The remainder of the defect was covered with split-thickness skin grafts. This patient made a full recovery.

    • Given the potential fulminant nature of this necrotizing process, consider repeated operative debridement procedures to ensure complete eradication of the infection.
    • Once the results of the tissue cultures are known, alter the antibiotic regimen to cover the causative organisms. Continue antibiotics for 10-14 days or until reconstruction is accomplished.
    • If the perineal involvement is extensive, fecal diversion should be considered at subsequent operative explorations to eliminate the potential for fecal contamination of the wounds. Fecal diversion is usually unnecessary when the necrosis is limited to the genitalia but is mandatory when the perianal area is extensively involved.
    • Urinary diversion is accomplished with a urethral catheter in most cases. Suprapubic cystostomy is used when urethral drainage of the bladder is not possible because of pathology (eg, stricture disease, prostatic hypertrophy).
    • The testicles are often spared in the necrotizing process. If uninvolved, place the exposed testicle in a subcutaneous pocket to prevent desiccation. If a testicle is involved in the necrotic process or its viability is questioned, perform orchiectomy.
    • Once the infection is eradicated, healthy granulation tissue develops; this signifies the time to proceed to reconstruction.
    • Vacuum-assisted closure (VAC) has shown great promise in the hastening wound healing in these patients with Fournier gangrene.36 Application after initial debridement may shorten the hospital stay and may speed up the grafting and flap placement process.
  • Options for reconstruction
    • Primary closure of the skin, if possible
    • Local skin flap coverage
    • Split-thickness skin grafts (see Image 8)

      The same patient depicted in Images 6 and 7. Foll...

      The same patient depicted in Images 6 and 7. Following resolution of the infection, the wound was covered with a split-thickness skin graft. The option of delayed primary closure of this wound was not chosen in this patient because of concern for tension on the closure. Courtesy of Thomas A. Santora, MD.

      The same patient depicted in Images 6 and 7. Foll...

      The same patient depicted in Images 6 and 7. Following resolution of the infection, the wound was covered with a split-thickness skin graft. The option of delayed primary closure of this wound was not chosen in this patient because of concern for tension on the closure. Courtesy of Thomas A. Santora, MD.

    • Muscular flaps, which are used to fill a cavity (eg, ischiorectal space)

Complications

The main complication associated with Fournier disease is unresolved sepsis, often caused by one of the following:

  • Unrecognized cause of the infection (eg, perforated peptic ulcer disease, appendicitis, diverticulitis) or extension of the necrotizing process outside the obvious wound (A CT scan is helpful for evaluating these two possibilities.)
  • Complication of severe acute illness (eg, line sepsis, bacterial endocarditis, pneumonia)
  • The plethora of comorbid conditions (eg, acute myocardial infarction, respiratory failure, pressure ulcerations, delirium) or the bedrest conditions imposed on patients who are acutely ill (eg, pulmonary embolus, deep venous thrombosis, atelectasis, pneumonia)

More on Fournier Gangrene

Overview: Fournier Gangrene
Workup: Fournier Gangrene
Treatment: Fournier Gangrene
Follow-up: Fournier Gangrene
Multimedia: Fournier Gangrene
References

References

  1. Wilson B. Necrotizing fasciitis. Am Surg. Apr 1952;18(4):416-31. [Medline].

  2. Corman JM. Classic articles in colonic and rectal surgery. Dis Colon Rectum. 1988;31:984-8.

  3. Ekelius L, Björkman H, Kalin M, Fohlman J. Fournier's gangrene after genital piercing. Scand J Infect Dis. 2004;36(8):610-2. [Medline].

  4. Paty R, Smith AD. Gangrene and Fournier's gangrene. Urol Clin North Am. Feb 1992;19(1):149-62. [Medline].

  5. Ayumba BR, Magoha GA. Epidemiological aspects of Fournier's gangrene at Kenyatta National Hospital, Nairobi. East Afr Med J. Oct 1998;75(10):586-9. [Medline].

  6. Ayumba BR, Magoha GA. Management of Fournier's gangrene at the Kenyatta National Hospital, Nairobi. East Afr Med J. Jun 1998;75(6):370-3. [Medline].

  7. Smith GL, Bunker CB, Dinneen MD. Fournier's gangrene. Br J Urol. Mar 1998;81(3):347-55. [Medline].

  8. Clayton MD, Fowler JE Jr, Sharifi R, Pearl RK. Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. Surg Gynecol Obstet. Jan 1990;170(1):49-55. [Medline].

  9. Gamagami RA, Mostafavi M, Gamagami A, Lazorthes F. Fournier's gangrene: an unusual presentation for rectal carcinoma. Am J Gastroenterol. Apr 1998;93(4):657-8. [Medline].

  10. Gould SW, Banwell P, Glazer G. Perforated colonic carcinoma presenting as epididymo-orchitis and Fournier's gangrene. Eur J Surg Oncol. Aug 1997;23(4):367-8. [Medline].

  11. Brings HA, Matthews R, Brinkman J, Rotolo J. Crohn's disease presenting with Fournier's gangrene and enterovesical fistula. Am Surg. May 1997;63(5):401-5. [Medline].

  12. Mouraviev VB, Pautler SE, Hayman WP. Fournier's gangrene following penile self-injection with cocaine. Scand J Urol Nephrol. 2002;36(4):317-8. [Medline].

  13. Faber HJ, Girbes AR, Daenen S. Fournier's gangrene as first presentation of promyelocytic leukemia. Leuk Res. May 1998;22(5):473-6. [Medline].

  14. Martinelli G, Alessandrino EP, Bernasconi P, et al. Fournier's gangrene: a clinical presentation of necrotizing fasciitis after bone marrow transplantation. Bone Marrow Transplant. Nov 1998;22(10):1023-6. [Medline].

  15. Kohagura K, Sesoko S, Tozawa M, et al. [A female case of Fournier's gangrene in a patient with lupus nephritis]. Nippon Jinzo Gakkai Shi. Jul 1998;40(5):354-8. [Medline].

  16. Roca B, Cuñat E, Simón E. HIV infection presenting with Fournier's gangrene. Neth J Med. Oct 1998;53(4):168-71. [Medline].

  17. Rajbhandari SM, Wilson RM. Unusual infections in diabetes. Diabetes Res Clin Pract. Feb 1998;39(2):123-8. [Medline].

  18. Mergenhagen SE, Thonard JC, Scherp HW. Studies on synergistic infections. I. Experimental infections with anaerobic streptococci. J Infect Dis. Jul-Aug 1958;103(1):33-44. [Medline].

  19. Meleney FL. Hemolytic Streptococcus gangrene. Arch Surg. 1924;9:317-21.

  20. Moses AE. Necrotizing fasciitis: flesh-eating microbes. Isr J Med Sci. Sep 1996;32(9):781-4. [Medline].

  21. Benizri E, Fabiani P, Migliori G, et al. Gangrene of the perineum. Urology. Jun 1996;47(6):935-9. [Medline].

  22. Benchekroun A, Lachkar A, Bjijou Y, et al. [Gangrene of the external genital organs. Apropos of 55 cases]. J Urol (Paris). 1997;103(1-2):27-31. [Medline].

  23. Ben-Aharon U, Borenstein A, Eisenkraft S, et al. Extensive necrotizing soft tissue infection of the perineum. Isr J Med Sci. Sep 1996;32(9):745-9. [Medline].

  24. Basoglu M, Gül O, Yildirgan I, Balik AA, Ozbey I, Oren D. Fournier's gangrene: review of fifteen cases. Am Surg. Nov 1997;63(11):1019-21. [Medline].

  25. Goyette M. Group A streptococcal necrotizing fasciitis Fournier's gangrene--Quebec. Can Commun Dis Rep. Jul 1 1997;23(13):101-3. [Medline].

  26. Fan CM, Whitman GJ, Chew FS. Radiologic-Pathologic Conferences of the Massachusetts General Hospital. Necrotizing fasciitis of the scrotum (Fournier's gangrene). AJR Am J Roentgenol. May 1996;166(5):1164. [Medline].

  27. Rajan DK, Scharer KA. Radiology of Fournier's gangrene. AJR Am J Roentgenol. Jan 1998;170(1):163-8. [Medline].

  28. Kane CJ, Nash P, McAninch JW. Ultrasonographic appearance of necrotizing gangrene: aid in early diagnosis. Urology. Jul 1996;48(1):142-4. [Medline].

  29. Sherman J, Solliday M, Paraiso E, Becker J, Mydlo JH. Early CT findings of Fournier's gangrene in a healthy male. Clin Imaging. Nov-Dec 1998;22(6):425-7. [Medline].

  30. Wysoki MG, Santora TA, Shah RM, Friedman AC. Necrotizing fasciitis: CT characteristics. Radiology. Jun 1997;203(3):859-63. [Medline].

  31. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. Jul 1988;158(1):23-8. [Medline].

  32. Cawley MJ, Briggs M, Haith LR Jr, Reilly KJ, Guilday RE, Braxton GR. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review. Pharmacotherapy. Sep 1999;19(9):1094-8. [Medline].

  33. Korhonen K, Hirn M, Niinikoski J. Hyperbaric oxygen in the treatment of Fournier's gangrene. Eur J Surg. Apr 1998;164(4):251-5. [Medline].

  34. Pizzorno R, Bonini F, Donelli A, Stubinski R, Medica M, Carmignani G. Hyperbaric oxygen therapy in the treatment of Fournier's disease in 11 male patients. J Urol. Sep 1997;158(3 Pt 1):837-40. [Medline].

  35. Hollabaugh RS Jr, Dmochowski RR, Hickerson WL, Cox CE. Fournier's gangrene: therapeutic impact of hyperbaric oxygen. Plast Reconstr Surg. Jan 1998;101(1):94-100. [Medline].

  36. Kovacs LH, Kloeppel M, Papadopulos NA, Reeker W, Biemer E. Necrotizing fasciitis. Ann Plast Surg. Dec 2001;47(6):680-2. [Medline].

  37. Corman JM, Moody JA, Aronson WJ. Fournier's gangrene in a modern surgical setting: improved survival with aggressive management. BJU Int. Jul 1999;84(1):85-8. [Medline].

  38. Chen CS, Liu KL, Chen HW, Chou CC, Chuang CK, Chu SH. Prognostic factors and strategy of treatment in Fournier's gangrene: a 12-year retrospective study. Changgeng Yi Xue Za Zhi. Mar 1999;22(1):31-6. [Medline].

  39. Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI. Outcome prediction in patients with Fournier's gangrene. J Urol. Jul 1995;154(1):89-92. [Medline].

  40. Corcoran AT, Smaldone MC, Gibbons EP, Walsh TJ, Davies BJ. Validation of the Fournier's gangrene severity index in a large contemporary series. J Urol. Sep 2008;180(3):944-8. [Medline].

  41. Norton KS, Johnson LW, Perry T, et al. Management of Fournier's gangrene: an eleven year retrospective analysis of early recognition, diagnosis, and treatment. Am Surg. Aug 2002;68(8):709-13. [Medline].

  42. Papachristodoulou AJ, Zografos GN, Papastratis G, Papavassiliou V, Markopoulos CJ, Mandrekas D, et al. Fournier's gangrene: still highly lethal. Langenbecks Arch Chir. 1997;382(1):15-8. [Medline].

  43. Hejase MJ, Simonin JE, Bihrle R, Coogan CL. Genital Fournier's gangrene: experience with 38 patients. Urology. May 1996;47(5):734-9. [Medline].

  44. Mindrup SR, Kealey GP, Fallon B. Hyperbaric oxygen for the treatment of fournier's gangrene. J Urol. Jun 2005;173(6):1975-7. [Medline].

  45. Nomikos IN. Necrotizing perineal infections (Fournier's disease): old remedies for an old disease. Int J Colorectal Dis. 1998;13(1):48-51. [Medline].

  46. Asci R, Sarikaya S, Büyükalpelli R, Yilmaz AF, Yildiz S. Fournier's gangrene: risk assessment and enzymatic debridement with lyophilized collagenase application. Eur Urol. 1998;34(5):411-8. [Medline].

  47. el Khader K, el Fassi J, Nouri M, Ibn Attya A, Hachimi M, Lakrissa A. [Fournier's gangrene. Analysis of 32 cases]. J Urol (Paris). 1997;103(1-2):32-4. [Medline].

  48. Kovacs LH, Kloeppel M, Papadopulos NA, et al. Necrotizing fasciitis. Ann Plast Surg. Dec 2001;47(6):680-2.

  49. Loulergue P, Mahe V, Bougnoux ME, Poiree S, Hot A, Lortholary O. Fournier's gangrene due to Candida glabrata. Med Mycol. Mar 2008;46(2):171-3. [Medline].

Further Reading

Keywords

Fournier gangrene, Fournier's gangrene, genital gangrene, penile gangrene, idiopathic gangrene of the penis and scrotum, spontaneous fulminant gangrene of the scrotum, necrotizing fasciitis of the scrotum, necrotizing fasciitis of the male genitalia, infectious gangrene of the scrotum and penis, scrotal gangrene, synergistic gangrene of the male genitalia, gangrenous erysipelas of the scrotum, streptococcal gangrene of the scrotum, necrotizing fasciitis, genital necrotizing fasciitis, scrotal necrotizing fasciitis, penile necrotizing fasciitis, testicular necrotizing fasciitis, Fournier’s disease, Fournier disease

Contributor Information and Disclosures

Author

Thomas Santora, MD, Professor and Vice-Chair for Clinical Affairs, Department of Surgery, Temple University Hospital and School of Medicine
Thomas Santora, MD is a member of the following medical societies: American Association for the Surgery of Trauma, American College of Surgeons, American Trauma Society, Association for Academic Surgery, and Eastern Association for the Surgery of Trauma
Disclosure: Nothing to disclose.

Coauthor(s)

Daniel B Rukstalis, MD, Director of Urological Services, Geisinger Medical Center, Geisinger Medical Group
Daniel B Rukstalis, MD is a member of the following medical societies: American Association for the Advancement of Science and American Urological Association
Disclosure: Nothing to disclose.

Medical Editor

Alex Jacocks, MD, Program Director, Professor, Department of Surgery, University of Oklahoma School of Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

David L Morris, MD, PhD, Professor, Department of Surgery, St George Hospital, University of New South Wales, Australia
Disclosure: Nothing to disclose.

CME Editor

J Stuart Wolf Jr, MD, FACS, David A Bloom Professor of Urology, Director of Division of Minimally Invasive Urology, Department of Urology, University of Michigan
J Stuart Wolf Jr, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Catholic Medical Association, Endourological Society, Society for Urology and Engineering, Society of Laparoendoscopic Surgeons, Society of University Urologists, and Society of Urologic Oncology
Disclosure: Terumo Corporation Consulting fee Consulting; Omeros Corporation Consulting fee Consulting

Chief Editor

Bradley Fields Schwartz, DO, FACS, Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine
Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, and Society of University Urologists
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.